How to manage rheumatic patients during the coronavirus pandemic.

[1]  Nicola Clementi,et al.  Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro , 2020, bioRxiv.

[2]  J. Portnoy,et al.  Telemedicine in the Era of COVID-19 , 2020, The Journal of Allergy and Clinical Immunology: In Practice.

[3]  F. Ingegnoli,et al.  COVID-19 infection and rheumatoid arthritis: Faraway, so close! , 2020, Autoimmunity Reviews.

[4]  D. Raoult,et al.  New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? , 2020, International Journal of Antimicrobial Agents.

[5]  Xu Liu,et al.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[7]  Jianjun Gao,et al.  Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. , 2020, Bioscience trends.

[8]  T. Dörner,et al.  Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology , 2020, Nature Reviews Rheumatology.

[9]  V. Novack,et al.  Short- and long-term mortality due to sepsis in patients with rheumatoid arthritis , 2017, Rheumatology International.

[10]  G. Ruiz-Irastorza,et al.  Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies , 2013, Lupus.

[11]  J. Kremer,et al.  High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis , 2011, Annals of the rheumatic diseases.